Kenvue (KVUE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kenvue

NYSE•Consumer Defensive•Household & Personal Products

$17.92+0.01(<0.01%)After hours

Market Cap

$34.18B

P/E

20.6x

P/S

2.2x

P/B

3.2x

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

How this company scores

GoodMetricSide Score: 76/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability22/25

Growth15/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 20.6x5y range 20.6x – 43.0x

Currently near its 11-quarter median.

P/S · 2.2x5y range 2.1x – 3.0x

Currently near its 11-quarter median.

P/B · 3.2x5y range 2.3x – 4.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Revenue Decline

Watch

Revenue has softened, declining in 4 quarters. Watch for further erosion.

Price & Volume

Market Cap $34.18B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $15.41B
Q. Revenue: $3.96B
TTM EBITDA: $3.20B
TTM Op. Income: $2.63B
Q. Op. Income: $699.00M
TTM Net Income: $1.66B
Q. Net Income: $456.00M
EPS: $0.24
Shares Out.: $1.92B

$15.41B in TTM revenue grew 1.8% YoY, reaching $3.96B last quarter. TTM EBITDA of $3.20B and TTM operating income of $2.63B show growth is flowing through to the bottom line. TTM net income of $1.66B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.2%
EBITDA Margin: 21.3%
Op. Margin: 17.7%
Net Margin: 11.5%

Op. margin of 17.7% is down 0.4% YoY — costs are rising relative to revenue. Net margin at 11.5% and gross margin of 58.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 2% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 20.6x
P/S Ratio: 2.2x
P/B Ratio: 3.2x

At 20.6x P/E, the stock trades within typical market levels. P/S of 2.2x and P/B of 3.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $26.73B
Cash: $1.11B
Long-Term Debt: $7.07B
Book Value: $10.55B
D/E Ratio: 0.7
Debt/EBITDA: 8.4

With $26.73B in assets and $7.07B in long-term debt, D/E is 0.7and book value is $10.55B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 8% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $688.00M
TTM Free Cash Flow: $1.91B
FCF Margin: 12.4%
FCF / Net Income: 1.2

TTM FCF of $1.91B on $688.00M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 6 consecutive quarters — an improving trend.